About AB Science
AB Science is a publicly listed company based in Paris (France) founded in 2001. Tyrosine kinase inhibitors are developed for multiple disease indications. The company has 39 employees. AB Science offers products and services including Masitinib and AB8939. Its focus areas include Life Sciences, Oncology, Drugs and Pan Cancer. Its legal entity is AB SCIENCE USA, LLC.
Company details
AB Science was founded in 2001 and is headquartered in Paris, France. Operations focus on the biotechnology sector, where small-molecule drugs are developed for oncology, neurodegenerative, and inflammatory conditions. The lead product, masitinib, is a selective tyrosine kinase inhibitor targeted at various indications. Another candidate, AB8939, functions as a microtubule destabilizer for similar therapeutic areas. Development efforts emphasize innovative inhibitors to address unmet medical needs.
- Headquarters Paris, France
- Employees 39
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website ab-science.com
- Social LinkedIn X
- Legal Name Ab Science Sa
- Annual Revenue$1.37 M (USD)9.51as on Dec 31, 2025
- Net Profit-$1.83 M (USD)80.12as on Dec 31, 2025
- EBITDA-$1.13 M (USD)87.61as on Dec 31, 2025
- Latest Funding Round$2.02M (USD), Post-IPO
Jul 2026
- Employee Count39
Products & Services of AB Science
AB Science offers a comprehensive portfolio of products and services, including Masitinib and AB8939.
Compound for treating neurodegenerative and inflammatory diseases.
Compound targeting cancers like acute myeloid leukemia.
Funding Insights of AB Science
- Total Rounds 10
- Last Round Post-IPO — $2.02M
- First Round $16.3M
(Mar 2017)
All 10 funding rounds of AB Science with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2026 | $2.02M | Post-IPO | – | – | – |
| May 2026 | $2.99M | Post-IPO | – | – | – |
| Oct 2025 | $3.27M | Post-IPO | – | – | – |
| Jul 2025 | $2.26M | Post-IPO | – | – | – |
| May 2025 | $2.02M | Post-IPO | – | – | – |
| Apr 2023 | $16.48M | Post-IPO | – | – | – |
| Mar 2020 | $7.06M | Post-IPO | – | – | – |
| Aug 2019 | $12.49M | Post-IPO | – | – | – |
| Apr 2017 | $20.28M | Post-IPO | – | – | – |
| Mar 2017 | $16.3M | Post-IPO | – | – | – |
IPO & Listings of AB Science
AB Science is a publicly listed company on the EURONEXT with ticker symbol AB in France, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date21 Apr 2010
- Listed onEuronext: AB
- Listed entityAB Science SA
- Exchange sectorHealth technology
- ISINFR0010557264
- Share price0.56 EUR (-2.93% on the day) · 2026-10-14
- Market capitalisation55,987,853.00 EUR
- EPS (diluted, trailing year)-0.08 EUR
- Volume (last session)78,838
Financials of AB Science
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 1.2M EUR | -1.6M EUR | -959,000 EUR |
| 2024 | 1.1M EUR | -7.8M EUR | -7.7M EUR |
| 2023 | 970,000 EUR | -12.0M EUR | -14.6M EUR |
| 2022 | 958,000 EUR | -13.6M EUR | -19.1M EUR |
| 2021 | 1.6M EUR | -14.5M EUR | -16.8M EUR |
Detailed financial statements for AB Science
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of AB Science
4 dated milestones of AB Science across 25 years, from founding to its latest funding, stage changes and deals.
- Founded AB Science is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $16.3M.
- Funding Latest funding round, Post-IPO, of $2.0M.
Web traffic of AB Science
The website of AB Science (ab-science.com) receives about 6.7K visits a month and ranks #3,021,575 among all websites worldwide, #4,007 in Biotechnology and Pharmaceuticals.
- Monthly visits6.7K
▼ 5.7% vs previous month
- Unique visitors2.9K
per month
- Global rank#3,021,575
among all websites
- Category rank#4,007
Health · Biotechnology and Pharmaceuticals
- Bounce rate43%
- Pages per visit1.5
- Average visit10 sec
- DevicesDesktop 40% · Mobile 60%
Websites whose visitors overlap most with AB Science. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
pfizer.it | pfizer.it | 100% | #2,175,497 | – | |
boehringer-ingelheim.it | boehringer-ingelheim.it | 100% | – | ||
janssen-italia.it | janssen-italia.it | 100% | – | ||
bayer.it | bayer.it | 100% | #1,680,979 | – | |
| abivax.com | 91% | 39.3K | #727,495 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 13 similar websites and full traffic analytics for AB Science
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 13 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Ab Science
Complete news archive for AB Science
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about AB Science
AB Science was founded in 2001 and raised its 1st funding round 16 years after it was founded.
AB Science is headquartered in Paris, France.
AB Science has 39 employees.
Annual revenue of AB Science is $1.37M as on Dec 31, 2025.
AB Science was founded in 2001 and is headquartered in Paris, France. Operations focus on the biotechnology sector, where small-molecule drugs are developed for oncology, neurodegenerative, and inflammatory conditions. The lead product, masitinib, is a selective tyrosine kinase inhibitor targeted at various indications. Another candidate, AB8939, functions as a microtubule destabilizer for similar therapeutic areas. Development efforts emphasize innovative inhibitors to address unmet medical needs.
AB Science offers Masitinib and AB8939.
Yes, AB Science is publicly traded on EURONEXT under the ticker symbol AB.
AB Science operates through Ab Science Usa, Llc.